Abstract
Parkinson’s disease (PD) is a late-onset, progressive disease characterized by motor and postural defects. Pathologically, PD is marked by specific nigrostriatal dopaminergic degeneration and the formation of Lewy bodies, cytoplasmic inclusions containing ubiquitin and a-synuclein.l Current therapeutic approaches for PD focus on alleviating symptoms that occur in the late-stages. An understanding of PD pathogenesis and the development of accurate models of the disease are essential for the development of novel therapies targeted at preventing the progression of PD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
M. Irizarry, J. Growdon, T. Gomez-Isla, K. Newell, J. M. George, D. F. Clayton, et al, Nigral and cortical Lewy bodies and dystrophic nigral neurities in Parkinson’s disease and cortical Lewy body disease contain a-synuclein immunoreactivity, J. Neuropathol. Exp. Neurol. 57(4), 334–337 (1998).
R. Kruger, W. Kuhn, T. Muller, D. Woitalla, M. Graeber, S. Kosel, et al, Ala30Pro mutation in the gene encoding a-synuclein in Parkinson’s disease, Nature Genet. 18(2), 106–108 (1998).
M.H. Polymeropoulos, C. Lavedan, E. Leory, S.E. Ide, A. Dehejia, A. Dutra, et al, Mutation in the asvnuclein gene identified in families with Parkinson’s disease. Science 276 (5321). 2045–2047 (1997).
T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S. Minoshima, et al, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature 392(6676), 605–608 (1998).
A. Menegon, P. G. Board, A. C. Blackburn, G. D. Mellick, and D. G. LeCouteur, Parkinson’s disease, pesticides, and glutathione transferase polymorphisms. Lancet 352(9137), 1344–1346 (1998).
P. G. Butterfield, B. G. Valanis, P. S. Spencer, C. A. Lindeman, and J. G. Nutt, Environmental antecedents of young-onset Parkinson’s disease, Neurol. 43(6), 1150–1158 (1993).
J. W. Langston, P.A. Ballard, J. W. Tetrud, and I. Irwin, Chronic parkinsonism in humans due to a product of meridine-analog synthesis, Science, 219(4587), 979–980 (1983).
K. F. Tipton and T. P. Singer, Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds, J. Neurochem., 61(4), 1191–1206 (1993).
W. J. Nicklas, I. Vyas, and R. E. Heikkila, Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36(26), 2503–2508.
W. D. Parker, S. J. Boyson, and J. K. Parks, Electron transport chain abnormalities in idiopathic Parkinson’s disease, Ann. Neurol. 26(6), 719–723 (1989).
A. H. Schapira, J. M. Cooper, D. Dexter, P. Jenner, J. B. Clark, and C. J. Marsden, Mitochondrial deticitis in Parkinson’s disease, Lancet 1(8649), 1269 (1989).
Y. Mizuno, H. Yoshino, S. Ikebe, N. Hattori, T. Kobayashi, T. Shimoda-Mastubayashi, et al., Mitochondrial dysfunction in Parkinson’s disease, Ann. Neurot. 40(3 Suppl 1), S99–S109 (1998).
R. Betarbet, T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov, and J. T. Greenamyre, Chronic systemic pesticide exposure reproduces features of Parkinson’s disease, Nature Neurosci. 3(12),1301–1306 (2000).
D. S. Higgins Jr. and J. T. Greenamyre, [3H] dihydrorotenone binding to NADH: Ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study, J. Neurochem. 66(12), 3807–3816 (1996).
O. Homykiewicz, Dopamine (3-hydroxytyramine) and brain function, Pharmacol. Rev. 18(2), 925–963 (1966).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic / Plenum Publishers, New York
About this chapter
Cite this chapter
Sherer, T.B., Betarbet, R., Greenamyre, J.T. (2002). Chronic Complex I Inhibition Reproduces Features of Parkinson’s Disease. In: Mizuno, Y., Fisher, A., Hanin, I. (eds) Mapping the Progress of Alzheimer’s and Parkinson’s Disease. Advances in Behavioral Biology, vol 51. Springer, Boston, MA. https://doi.org/10.1007/978-0-306-47593-1_45
Download citation
DOI: https://doi.org/10.1007/978-0-306-47593-1_45
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0973-5
Online ISBN: 978-0-306-47593-1
eBook Packages: Springer Book Archive